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ABSTRACT
Introduction: The purpose of this study was to
quantify United States (US) and United
Kingdom (UK) physicians’ preferences for
attributes of type 2 diabetes treatments.
Methods: Samples of general practitioners
(GPs) and endocrinologists in the US (n = 204)
and the UK (n = 200) completed a discrete-
choice experiment in which respondents chose
between pairs of hypothetical type 2 diabetes
treatments in a series of trade-off questions. The
questions described hypothetical injectable
treatments with differing levels of attributes,
such as glucose control and treatment side
effects. Relative importance of attributes was
estimated by a multivariate regression model for
limited dependent variables. These results were
used to calculate how the predicted probability
of choosing hypothetical type 2 diabetes
treatments varies with changes in given
attributes.
Results: The most important attributes to
physicians were glucose control, risk of a fatal
myocardial infarction (MI), and weight change.
For US physicians, glucose control was about
twice as important as gastrointestinal side
effects, 5 times more important than changes
in depression symptoms, and 20 times more
important than liver monitoring. For UK
physicians, reduction in MI risk was about 1.5
times more important than glucose control, 2.5
times more important than gastrointestinal side
effects, and 10 times more important than liver-
monitoring requirements. Preferences were
similar among physicians in the US and the
UK and among GPs and endocrinologists.
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Conclusions: Physicians valued type 2 diabetes
treatments that go beyond glycemic control,
although mitigating different complications
and comorbidities was not equally as important.
Keywords: Conjoint analysis; Diabetes
treatments; Discrete-choice-experiment survey;
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Patient preferences; Type 2 diabetes mellitus
INTRODUCTION
Diabetes causes significant clinical and
economic burden in the US and the UK [1–4].
Achieving effective glycemic control in patients
with diabetes reduces microvascular
complications, as well as long-term risks of
macrovascular disease [5]. Even with glycemic
control, complications and comorbidities,
including cardiovascular disease, depression,
and obesity, have significant effects on both
the clinical and economic burden of type 2
diabetes. In particular, patients with type 2
diabetes have two to four times higher risk of
cardiovascular disease than adults without
diabetes, which constitutes the largest share of
the cost of diabetes [1, 5, 6]. Depression is at
least twice as prevalent among individuals with
diabetes as it is among non-diabetics, increasing
the risk of diabetic complications [7, 8]. Finally,
obese adults are much more likely to have
diabetes than adults who are not obese [3].
About 13% of the expenditures on metabolic
conditions (including the estimated annual
costs of $92.6 billion on obesity in the US) are
attributable to diabetes [3, 9, 10]. In addition,
liver abnormalities are more prevalent among
individuals with diabetes; thus, managing
diabetes could be complicated by liver-related
alterations in drug metabolism, drug
interactions, and risk of hepatotoxicity [11].
An additional challenge is that almost one-
third of diabetic patients do not adhere to their
treatment regimen, leading to poorer glycemic
control and increased risk of complications,
hospitalizations, and death [12–14]. A recent
review identified more frequent or complex
dosing, treatment-related weight gain,
persistent gastrointestinal (GI) side effects, and
depression to be among the factors that impair
adherence [15].
Diabetes outcomes are improved when
management goes beyond glycemic control to
managing comorbidities and complications [5],
and such therapies have been a focus of research
and clinical practice [16]. However, little is
known about how prescribing physicians
weigh the relative importance of glucose
control, managing comorbidities and
complications, and other treatment attributes
that could affect adherence. The objective of
this study was to quantify US and UK
physicians’ preferences for extra-glycemic
benefits of type 2 diabetes relative to other
attributes of type 2 diabetes treatments. There
are no type 2 diabetes treatments with proven
depression benefits, and most treatments (with
the exception of thiazolidinediones) do not
require liver monitoring. Thus, the latter two
outcomes are novel with respect to existing
treatments, and this study is exploratory in
terms of understanding preferences for these
outcomes.
A discrete-choice-experiment (DCE) survey
provided data on physician respondents’
evaluations of pairs of hypothetical diabetes
treatments. Treatment profiles described
hypothetical injectable treatments with
differing levels of treatment attributes. DCE is
a valid and reliable survey technique for
eliciting trade-offs to quantify the relative
importance respondents assign to attributes
and outcomes of health interventions [17, 18].
444 Diabetes Ther (2013) 4:443–459
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These methods increasingly are used to quantify
preferences for treating diabetes and other
health conditions [19–22].
MATERIALS AND METHODS
A DCE is based on the principle that medical
treatments are comprised of multiple
characteristics. Physicians’ disposition to
prescribe a treatment depends on the
characteristics of both the treatment and the
patient being treated. In a DCE, respondents
make hypothetical prescribing decisions about
constructed treatment alternatives. The
researcher controls the features of the
treatment alternatives and the patient
characteristics; physicians’ patterns of choices
are analyzed to estimate the implicit relative
importance weights physicians use to identify
preferred treatment alternatives [17, 23].
Survey Development, Pretests,
and Administration
This study described hypothetical injectable
type 2 diabetes treatments using seven
treatment features (or attributes) based on
published literature, consultation with clinical
experts, and one-on-one interviews with
physicians. The treatments of interest were
non-insulin injectables used to treat patients
who had failed to respond to two or three oral
medications. The following criteria were used to
identify attributes that: (a) were of potential
therapeutic interest; (b) were clinically relevant;
(c) reflected other, nonclinical features of
concern to physicians; and/or (d) incorporated
physicians’ assessments of patient concerns.
The resulting attributes included: glucose
control [treated hemoglobin A1c (HbA1c)
levels], weight change, frequency of injection,
GI side effects, requirement for liver
monitoring, reduction in the 5-year risk of a
fatal myocardial infarction (MI), and reduction
in depression symptoms (Table 1).
The first section of the survey instrument
obtained information on physicians’
characteristics and experience in treating
patients with type 2 diabetes, as well as their
target level of glucose control for a type 2
diabetes patient with the following
characteristics: aged 45–65 years, obese class II
Table 1 Attributes and levels in type 2 diabetes
treatments surveys
Treatment attribute Level
Glucose control within 3 months Reduces HbA1c to 7.0%
Reduces HbA1c to 8.0%
Reduces HbA1c to 8.3%
Frequency of injections 2 injections/day
1 injection/day
1 injection every other day
1 injection/week
1 injection/month
Liver monitoring test Not required
Every month for the ﬁrst 3 months,
then quarterly as long as the patient
takes the medicine





Mild to moderate nausea, diarrhea,
and/or vomiting 3–4 times/week
None
Resolves after taking medicine for
2 weeks
Continues as long as patient takes
medicine
Changes in the risk of a fatal MI
over 5 years
No effect
Reduces 5-year risk of fatal MI by
5/1,000 (from 25/1,000 to 20/1,000)
Reduces 5-year risk of fatal MI by
15/1,000 (from 25/1,000 to
10/1,000)
Changes in depression symptoms No reduction in symptoms
From moderate to mild depression
From moderate to no depression
HbA1c hemoglobin A1c, MI myocardial infarction
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(body mass index 35–40 kg/m2), sedentary
lifestyle, moderate depression (a score of 15–19
on the Patient Health Questionnaire or a score
of 14–18 on the Hamilton Depression Rating
Scale), failure to respond to two or three oral
agents, and an HbA1c level of 9%. The second
section provided physician respondents with
definitions of the treatment attributes and
levels. Levels are specific values for the
treatment attributes. For example, weight
change is an attribute, which may take on
several possible levels such as 5% weight gain,
5% weight loss, or 10% weight loss. MI risks
were presented as frequencies [24]. The third
section included the trade-off questions that
asked physicians to choose which of two
hypothetical injectable treatment profiles they
would recommend as the next line of treatment
for the patient described (Fig. 1). All
hypothetical treatments were injectables,
because injectables often are the next line of
treatment for patients with the target profile.
The draft survey instrument was pretested
and refined based on in-depth, semistructured
interviews conducted with 15 physicians in the
US and 5 physicians in the UK. The objectives of
the pretests were to test the understandability of
the survey instrument, the appropriateness of
descriptive information, and the cognitive
burden of the trade-off questions. The US
pretests were completed first. The final survey
instrument for the US study was adapted for the
UK, and the UK pretests were used to evaluate
whether any cultural adaptations were
necessary to facilitate comprehension of the
survey concepts. As with the final sample,
Fig. 1 Example of a choice question for the patient proﬁled with a baseline HbA1c level of 9%. HbA1c hemoglobin A1c,
MI myocardial infarction
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around half of the US pretest respondents were
endocrinologists and the other half were
primary care physicians, internists, or family
practitioners. All UK pretest respondents were
general practitioners (GPs). The sample in the
UK had more experience, having been in
practice at least 16 years, while the US sample
had 1 to [25 years of experience. The UK
sample treated fewer patients per week, on
average, than the US sample. As described
below, similar differences in experience and
number of patients were observed in the full
study sample.
As a result of the pretest findings, the survey
instrument was adapted to improve the
descriptive information, and to reduce the
cognitive burden of the trade-off questions.
Statements were added regarding what the
hypothetical treatments would be in addition
to oral treatments, and that the treatment
outcomes already accounted for potential
interactions between glucose control, weight
loss, and MI risk. The question about target
HbA1c was added as physicians in the pretests
reported various HbA1c targets. In addition, the
glucose control attribute was changed from
describing changes in HbA1c (e.g., ‘‘0.7%
reduction’’) to describing the level to which
HbA1c was reduced. The GI side effects attribute
was refined to describe the severity of
symptoms, and a number of revisions to the
patient profile were made, including adding the
baseline level of HbA1c, narrowing the BMI
range from 35–45 kg/m2 to 40–45 kg/m2, and
dropping a second patient profile in which the
patient had no depression. A number of minor
editorial changes were also made based on the
pretests, and the final survey instrument was
programed for online administration.
To create the stimuli used to construct the
treatment profiles and pairs in the choice
questions, we employed a D-efficient
experimental design that resulted in 96
hypothetical treatment pairs [25–27]. Because
the quality of responses to choice questions
declines as the number of choice tasks increases,
leading to fatigue or cognitive burden [28, 29],
we divided the 96 paired comparisons in the
experimental design into eight survey versions,
each containing 12 choice questions. Each
physician was randomly assigned to one of the
eight versions of the experimental design, and
the order of the choice questions was also
randomized for each respondent.
Sample Recruitment
Physicians from an online opt-in physician
panel were invited to complete the survey by
e-mail. Physicians were recruited to the panel by
phone, online, or face-to-face interviews with
eligibility verified by a third party at their place
of work. As an opt-in panel, some potential
selection bias might exist, such as panel
members being more interested in and/or
more available for participation in survey
research. Invitations to participate in the
survey were sent to a random sample of panel
members who met the sample inclusion criteria:
(1) board-eligible or board-certified primary care
physicians in the US or GPs in the UK or
endocrinologists from either country, and (2)
treat patients with type 2 diabetes regularly. The
panel recruitment and study recruitment
procedures were the same in the US and the UK.
There are no power calculations for DCEs
[30]. Most published conjoint analysis studies
have a sample size between 100 and 300
respondents [18]. However, minimum sample
size depends on a number of criteria, including
the question format, the complexity of the
choice task, the desired precision of the results,
and the need to conduct subgroup analyses [30].
Given the results of a recent meta-regression
Diabetes Ther (2013) 4:443–459 447
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[30], the research team’s previous experience,
previously published studies [18], and an
interest in estimating separate results for the
UK and US samples, the study aimed to
interview 200 respondents in each country.
The Office of Research Protection and Ethics
at Research Triangle Institute granted a consent
exemption for this study, indicating that this
research did not meet the definition of human
(or animal) subjects research. US physicians
received a $55 cash honorarium for
participating in the survey. UK GPs received
the equivalent of a $66 cash honorarium, while
UK endocrinologists were given the equivalent
of $75. The 25-minute online survey was
administered in February 2012.
Statistical Analysis
The pattern of physicians’ responses to the
choice questions was analyzed using a
random-parameters logit (RPL) model. Results
from the RPL model are log-odds estimates
relative to the mean effect normalized at zero
and represent the weighted effect of each
treatment attribute level on respondents
choosing a profile containing that attribute
level. These estimates also can be interpreted
as preference weights indicating the relative
strength of preference for each attribute, and
differences between preference weights indicate
the relative strength of preference for changes
among attribute levels in the study.
The parameter estimates were combined
with the treatment profiles in the
experimental design to obtain a conjoint-
utility index that indicated the average value
score that physicians would assign to
prescribing the treatment of interest to the
target patient. The conjoint-utility index was
used to examine how predicted choice
probabilities (the likelihood that one
treatment would be chosen over another
treatment) would change in response to




E-mail invitations to participate in the survey
were sent to 691 physicians in the US and 1,915
physicians in the UK. Of these, 264 US
physicians (38.2%) and 306 UK physicians
(15.9%) responded. Of the physicians who
responded, 204 (77.3%) in the US and 200
(65.4%) in the UK met the inclusion criteria and
completed the survey.
One respondent in each of the US and UK
samples had no variation in their treatment-
profile choices (always picked treatment A or
treatment B). They were deleted from the
sample as this lack of variation in response
likely indicated that they did not pay attention
to the choice questions. The final sample sizes
used for analysis were therefore 203 physicians
in the US and 199 in the UK.
The characteristics of the respondents the US
and UK samples are shown in Table 2. The
average UK physician was younger and had not
been in practice as long as the average US
physician (P\0.05). UK physicians treated
fewer patients than US physicians (P\0.05),
and a larger percentage of the UK physicians
selected higher target HbA1c levels for the
patient profile (P\0.01).
Preferences for Treatment Attributes
Figure 2 presents the estimated log-odds
preference estimates for US and UK physicians
and the 95% confidence intervals (CI) for the
seven treatment attributes. The estimated
448 Diabetes Ther (2013) 4:443–459
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Table 2 Summary of physicians’ characteristics








42 (20.7%) 47 (23.6%)
Mean respondent age in
years (SD)*,a
52.5 (9.5) 44.5 (8.2)
Number of years in
practice*,b
Less than 1 year 0 (0.0%) 0 (0.0%)
1–3 years 3 (1.5%) 0 (0.0%)
4–6 years 13 (6.4%) 11 (5.5%)
7–9 years 11 (5.4%) 12 (6.0%)
10–15 years 42 (20.7%) 73 (36.7%)
16–20 years 40 (19.7%) 46 (23.1%)
21–25 years 52 (25.6%) 37 (18.6%)
More than 25 years 42 (20.7%) 20 (10.1%)
Type of practicec Ofﬁce-based private practice (general practice)d 177 (87.2%) 96 (48.2%)
Hospital-based private practice (NHS hospital) 23 (11.3%) 108 (54.3%)
Academic hospital-based practice (private practice) 23 (11.3%) 10 (5.0%)
Other—not speciﬁed (other—not speciﬁed) 3 (1.5%) 0 (0.0%)
Respondent’s area of
specialization
Primary care (general practice)d 5 (2.5%) 93 (46.7%)
Family medicine (general medicine) 43 (21.2%) 11 (5.5%)
Internal medicine (N/A) 54 (26.6%) N/A
Endocrinology (endocrinology/diabetology) 100 (49.3%) 95 (47.7%)
Other (specialty not speciﬁed) 1 (0.5%) 0 (0.0%)
Number of patients with
type 2 diabetes treated
each week*,b
5 patients or less 3 (1.5%) 4 (2.0%)
6–10 patients 7 (3.5%) 13 (6.5%)
11–20 patients 20 (9.9%) 45 (22.6%)
21–30 patients 44 (21.7%) 41 (20.6%)
31–40 patients 21 (10.3%) 32 (16.1%)
41–50 patients 38 (18.7%) 34 (17.1%)
51–75 patients 38 (18.7%) 19 (9.6%)
76–100 patients 22 (10.8%) 7 (3.5%)
More than 100 patients 10 (4.9%) 4 (2.0%)
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preference weights were generally consistent
with the natural order of attribute levels (e.g.,
lower HbA1c levels were preferred to higher
HbA1c levels). In three instances, the order of
measured preference weights were inconsistent
with the expected order of preference for the
attribute levels: one injection per day was
preferred to one injection every other day in
the US sample; one injection per week was
preferred to one injection every month in the
US sample; and GI side effects that resolved
after taking the medication for 2 weeks were
preferred to no GI side effects in the UK sample.
However, the differences between disordered
preference weights were not statistically
significant (P[0.05).
The difference between the most-preferred
and least-preferred level of an attribute
indicates the overall relative importance of
each attribute, conditional on the attributes
and levels shown in the survey. The overall
relative importance of all medication attributes
except glucose control were similar across the
US and UK samples (P[0.05), indicating that
physicians in the US and UK samples had
similar preferences. However, glucose control
was more important to US physicians than to
UK physicians (P\0.01).
Although glucose control was the most
important attribute for US physicians, the
relative importance of this attribute was not
significantly different from the importance of
reducing the 5-year risk of experiencing a fatal
MI, and change in body weight, which were the
second and third most important attributes. For
UK physicians in the sample, a reduction in the
Table 2 continued






Target level of HbA1c
for patient proﬁle*,e
4.0% 0 (0.0%) 1 (0.5%)
4.5% 1 (0.5%) 0 (0.0%)
5.0% 1 (0.5%) 4 (2.0%)
5.5% 2 (1.0%) 5 (2.5%)
6.0% 18 (8.9%) 9 (4.5%)
6.5% 81 (39.9%) 32 (16.1%)
7.0% 90 (44.3%) 79 (39.7%)
7.5% 10 (4.9%) 69 (34.7%)
N/A not applicable, NHS National Health Service, SD standard deviation, UK United Kingdom, US United States
* The difference between the characteristics in the US and UK samples was statistically signiﬁcant (P\0.01)
a A two-tailed t test was used to test for differences in mean age of the respondents between countries
b A Pearson’s Chi-squared test was used to test for differences in the patterns of responses in this categorical variable
between countries
c Results may sum to more than 100% because multiple responses were permitted
d Categories in parentheses are used in the UK version of the instrument. US and UK response categories shown in the
same cell are not necessarily parallel
e The patient proﬁled in the survey had the following characteristics: aged 45–65 years, obese class II (BMI 35–40 kg/m2),
sedentary lifestyle, moderate depression (score of 15–19 on the Patient Health Questionnaire or score of 14–18 on the
Hamilton Depression Rating Scale), and failure to respond to two or three oral agents
450 Diabetes Ther (2013) 4:443–459
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5-year risk of experiencing a fatal MI was the
most important attribute, followed by change
in body weight and glucose control. For
physicians in both countries, liver monitoring
and changes in depression symptoms were the
least important attributes of the medication.
GPs and endocrinologists in both countries
had similar preferences for treatment attributes.
In the US, preference weights for treatment
attributes were not significantly different
between GPs and endocrinologists (P[0.05).
However, in the UK, GPs had significantly lower
preference weights for liver monitoring
requirements than for no liver monitoring
requirements (P\0.05), whereas
endocrinologists did not distinguish between
medications requiring liver monitoring and
those that did not (P[0.05). The overall
Fig. 2 Estimated physicians’ preference weights for attributes of type 2 diabetes treatments (95% CIs). CI conﬁdence
interval, GI gastrointestinal, HbA1c hemoglobin A1c, MI myocardial infarction
Diabetes Ther (2013) 4:443–459 451
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relative importance of the remaining attributes
was not significantly different between UK
endocrinologists and GPs (P[0.05).
Figure 3 summarizes selected marginal
choice probabilities. All marginal choice
probabilities for the study are reported in an
online Appendix. For example, if a treatment
further improves HbA1c to 7.0% compared with
8.3% from a baseline level of 9%, the predicted
choice probability for that treatment increases
by 46 and 41 percentage points in the US and
UK samples, respectively. If depression benefits
improve from having no effect on moderate
depression symptoms to eliminating moderate
depression symptoms, the predicted choice
probability increases by 15 and 12 percentage
points in the US and UK samples, respectively.
The largest marginal choice probabilities in
both the US and UK samples were associated
with the largest changes in glucose control
Fig. 3 Selected estimates of marginal choice probabilities
for given improvements in medication attributesa,b. HbA1c
hemoglobin A1c, GI gastrointestinal, MI myocardial
infarction. aThe estimates implicitly assume that all
attributes other than that being valued remain unchanged.
bBrackets indicate 95% CIs. cThe patient proﬁle indicated
that the patient had a baseline HbA1c level of 9%. dThe
marginal choice probability was not calculated for this
change, because the estimated preferences for this sample
were not consistent with the natural ordering of the
medication feature
452 Diabetes Ther (2013) 4:443–459
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(from 8.3 to 7.0%), body weight (from 5%
weight gain to 20% weight loss), and the 5-year
risk of fatal MI (from 0 to 1.5%) (Fig. 3). In the
US sample, the smallest positive marginal
choice probability (4%) was associated with
changes in liver monitoring requirements
(from monitoring liver enzymes every month
for the first 3 months, then quarterly as long as
the patient takes the medicine, to no liver
monitoring requirements). In the UK sample,
the smallest positive marginal choice
probability (2%) was associated with changes
in depression symptoms.
Larger changes in GI side effects (from
continuing as long as patient takes medicine,
to either resolving after 2 weeks, or no GI side
effects) were more important than relatively
small changes in efficacy (from an HbA1c of 8.3
to 8.0%). Also, avoiding a 5% weight gain was
two to three times as important to physicians as
a 5% weight loss (Fig. 3). That is, avoiding a 5%
weight gain was predicted to increase the choice
probability by 18 or 21 percentage points,
depending on the sample, while a 5% weight
loss would increase the choice probability by
only 5 or 11 percentage points, on average.
To assess whether preference differences
were due to differences in age and experience
between the US and UK physicians, interaction
terms were added to the US and UK models.
Respondents’ reported age and years of
experience were interacted with each
treatment-attribute variable. The significance
of the all age interactions and all experience
interactions were tested separately; neither set
of interactions was found to be statistically
significant. Given that the estimates for the age
interaction terms and experience interaction
terms represent adjustments to preference
weights based on respondents’ age and years
of experience, respectively, these results
indicate that there was no statistically
significant effect of age or experience on
preferences for treatment attributes.
DISCUSSION
US and UK physicians in our sample valued type
2 diabetes treatments that would go beyond
glycemic control (i.e., HbA1c reduction) to help
control diabetes complications and
comorbidities. Physicians placed about as
much overall importance on cardiovascular
and weight benefits from diabetes treatments
as they placed on glucose control. Physicians
did not place much overall importance on
depression benefits or on requirements for
liver monitoring. We can only speculate about
why physicians value some extra-glycemic
benefits more than others. Physicians may
place greater weight on familiar attributes
than on attributes that are not present in
currently marketed diabetes medications.
Our survey-development activities indicated
that the links between diabetes and both weight
and cardiovascular outcomes were well
documented in the literature and well
understood by the physicians who participated
in the pretests. However, the links between type
2 diabetes and depression are not as well
documented, and pretest physicians varied in
the extent to which they considered diabetes and
depression to be correlated. Some physicians in
the pretest also noted that there are numerous
effective and inexpensive depression
medications currently available, and one
physician was concerned that combining
treatments would limit the extent to which
depression medications could be titrated.
On average, physicians placed a low weight
on liver monitoring requirements. Many of the
pretest physicians noted that they test diabetes
patients’ glucose levels frequently and can
Diabetes Ther (2013) 4:443–459 453
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conduct a liver monitoring test using the blood
drawn for that purpose without changing
treatment practices.
To our knowledge, there has been only one
previously published study of physicians’
preferences for type 2 diabetes treatments.
Porzsolt and colleagues [31] examined German
physicians’ relative preferences for glucose
control, side effects, convenience, and weight
change. Our findings are consistent with their
results, that weight change was as important to
German physicians as glucose control.
Larger changes in GI side effects were more
important than relatively small (and less
clinically meaningful) changes in efficacy, and
about as important as changes in fatal MI risk
and larger changes in weight loss. Many pretest
physicians stated that GI side effects were key
factors in treatment adherence and persistence.
Physicians had a strong aversion to weight
gain. This has been observed in other studies
[32] and suggests that avoiding even a relatively
small weight gain among patients like the one
described in the survey is more important than
a similarly small weight loss.
The study was conducted in the US and the
UK to explore physicians’ relative preferences for
extra-glycemic control outcomes in two settings
with different health care systems. Preferences
for type 2 diabetes treatment outcomes generally
were similar in the two samples. The three most
important attributes in the US sample were
glucose control, MI risk reduction, and weight
change, though the importance differences were
not statistically significant. The three most
important attributes in the UK sample were the
same, however, glucose control was less
important than MI risk reduction (P\0.05)
while the importance differences for weight
change and MI risk reduction were not
statistically different. Glucose control was less
important in the UK sample than in the US
sample (P\0.01). The reason for this is not clear
from the study, though differences in experience
and the health care systems could play a part.
Physicians in the UK were younger, on average;
had been practicing fewer years; and reported
higher target HbA1c levels for the patient
profiled in the survey than the US sample.
However, regression analyses suggested that age
and experience did not influence estimated
preferences. It is possible that the differences
are due to other differences in the study
populations, perhaps related to different
response rates in the US and the UK. The same
processes and criteria were used to recruit
physicians to the panel and to invite physicians
to participate in the study, but there are
potentially many other factors (e.g., holidays,
professional conferences, other studies in same
topic) that may have influenced enrollment
differently between the two countries.
However, we are not aware of any information
indicating that other factors may have affected
the response rates in this study.
Finally, at the time of the survey, the
American Diabetes Association standards of
care [33] indicated that lowering HbA1c to
\7% was a reasonable goal for many non-
pregnant adults and the National Institute for
Health and Care Excellence’s (NICE) quality
standard [34] defined clinical best practice as an
HbA1c target between 6.5 and 7.5%. Further,
the NICE quick reference guide for the
management of type 2 diabetes suggests that
target HbA1c levels be individualized, with less
stringent targets (\7.5%) for patients on
multiple therapies. The fact that guidelines in
the UK permitted higher HbA1c targets could
partially account for the fact that more UK
physicians than US physicians selected higher
HbA1c targets for the profiled patient.
Based on the pretests, discussions with
clinical experts, and reviews of publicly
454 Diabetes Ther (2013) 4:443–459
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available information about treatment and
referral guidelines, we hypothesized that there
would be differences in preferences between
endocrinologists on the one hand and all other
specialties that treat diabetes on the other.
While all of these specialties treat patients
with type 2 diabetes, it appears that
endocrinologists tend to see more advanced or
acute cases (though there may be exceptions).
The results indicated that the preferences of GPs
and endocrinologists were similar in both the
US and the UK, with the exception of
differences in preference for liver monitoring
among GPs and endocrinologists in the UK.
Despite the increasing use of DCE in health
applications to elicit preferences, this approach
has several limitations. First, physician choices
among hypothetical treatment profiles do not
have the same clinical consequences as actual
choices. We minimized the potential for
hypothetical bias by offering treatments that
mimic real-world trade-offs as closely as
possible. Second, physicians’ actual medication
choices may differ from predicted choices
because actual choices depend on a number of
clinical, institutional, and financial factors that
were beyond the scope of this study. This study
limited the characterization of hypothetical
diabetes treatments to seven treatment
attributes and excluded, for example, the risk
of pancreatitis. The US Food and Drug
Administration (FDA) [35] and recent literature
[36, 37] have highlighted controversies about
the possible risks of pancreatitis and pancreatic
cancer associated with some diabetes
treatments. Third, we cannot fully judge how
representative our physician samples were or
whether our results are generalizable to all
physicians in the US and the UK. Fourth, the
results we present relate to the patient profile
that physicians were asked to consider. The
sample was insufficient to explore physician
preferences for different patient profiles.
Finally, this study was not designed to support
development of treatment guidelines or to
provide clinical advice.
The study also has a number of strengths from
using best practices [17]. In particular, the survey
was carefully designed in collaboration with
clinical experts, was pretested using in-depth
interviews with physicians in the US and the UK,
and employed a state-of-the-art experimental
design. The choice data were analyzed using
advanced RPL methods that avoid estimation
bias from unobserved variation in preferences
across the sample and within-sample correlation
in the choice sequence for each respondent. We
also tested for the effect of systematic preference
differences by age, experience, and medical
specialty.
CONCLUSION
This study provides evidence that physicians
place about as much importance on a type 2
diabetes medication’s cardiovascular and
weight outcomes as they place on glucose
control. We found broad consensus about
treatment priorities among physicians with
different personal and professional
characteristics who treat diabetic patients.
These findings are consistent with the
challenges in diabetes care, in which
cardiovascular disease and obesity continue to
be problems. However, physicians place
relatively low importance on the attributes
describing depression benefits and liver
monitoring requirements in this study. As the
literature regarding the links between diabetes
and depression and liver abnormalities matures,
physicians and stakeholders should become
better informed about these links and
physicians’ relative preferences for type 2
diabetes treatments may change.
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APPENDIX
See Table 3.
Table 3 Estimates of marginal choice probabilities for given improvements in medication features (95% CI)
Medication feature Improvement in medication
feature
Marginal choice probability (in percentage points)
US physicians UK physicians
Level to which HbA1c is reduced 8.3–7.0% 46 (44, 48) 41 (37, 44)
8.0–7.0% 41 (37, 44) 33 (28, 38)
8.3–8.0% 20 (13, 27) 17 (9, 24)
Frequency of injection 2 injections/day to 1 injection/
month
25 (19, 32) 23 (17, 3)
1 injection/day to 1 injection/month 10 (1, 19) 20 (12, 28)
1 injection every other day to 1
injection/month
14 (5, 22) 11 (3, 20)
1 injection/week to 1 injection/
month
0a 8 (0, 15)
2 injections/day to 1 injection/week 26 (20, 32) 17 (10, 23)
1 injection/day to 1 injection/week 11 (4, 18) 13 (6, 20)
1 injection every other day to 1
injection/week
15 (7, 23) 4 (-5, 12)
2 injections/day to 1 injection every
other day
13 (6, 21) 14 (6, 21)
1 injection/day to 1 injection every
other day
0a 10 (1, 18)
2 injections/day to 1 injection/day 17 (9, 24) 4 (-4, 12)
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